Jubilant Life Sciences, a prominent player in the pharmaceutical and life sciences sector, is headquartered in Noida, India. Founded in 1978, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in contract manufacturing, active pharmaceutical ingredients (APIs), and drug delivery solutions, Jubilant Life Sciences is recognised for its commitment to quality and innovation. The company’s core offerings, which include a diverse range of generic pharmaceuticals and specialty chemicals, set it apart in a competitive market. With a focus on sustainability and advanced technology, Jubilant Life Sciences has achieved significant milestones, including multiple regulatory approvals and partnerships with leading global firms. This positions the company as a trusted partner in the healthcare industry, dedicated to improving patient outcomes worldwide.
How does Jubilant Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Jubilant Life Sciences's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Jubilant Life Sciences reported total carbon emissions of approximately 8620000 kg CO2e for Scope 1, 68152000 kg CO2e for Scope 2, and 737234000 kg CO2e for Scope 3, resulting in a combined total of about 76772000 kg CO2e for Scope 1 and 2. This reflects a slight increase in Scope 1 emissions from 8492000 kg CO2e in 2023, while Scope 2 emissions rose from 54703000 kg CO2e. The company has set ambitious climate commitments, aiming for net zero emissions by 2050 for both Scope 1 and Scope 2 emissions, with the target initiated in 2023. Jubilant Life Sciences has consistently disclosed emissions across all three scopes, with significant Scope 3 emissions, which accounted for the majority of their carbon footprint. The company’s emissions data is not cascaded from any parent organization, ensuring that their reported figures are independently sourced. Overall, Jubilant Life Sciences is actively working towards reducing its carbon footprint while adhering to industry standards for climate accountability.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jubilant Life Sciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
